JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21

Benzinga · 3d ago
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.